Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

Strong immunogenicity profile observed in study participants aged 5-17 years one month after the primary vaccination series Safety profile observed in pediatric participants similar to previously reported data in adult participants Pediatric...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials